Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters










Publication year range
1.
Oncogene ; 34(42): 5383-94, 2015 Oct 16.
Article in English | MEDLINE | ID: mdl-25619833

ABSTRACT

In the present study, we have assessed whether a putative calcium channel α2δ2 auxiliary subunit (CACNA2D2 gene) could be involved in prostate cancer (PCA) progression. We therefore carried out experiments to determine whether this protein is expressed in PCA LNCaP cells and in PCA tissues, and whether its expression may be altered during cancer development. In addition, we evaluated the influence on cell proliferation of overexpressing or downregulating this subunit. In vitro experiments show that α2δ2 subunit overexpression is associated with increased cell proliferation, alterations of calcium homeostasis and the recruitment of a nuclear factor of activated T-cells pathway. Furthermore, we carried out in vivo experiments on immuno-deficient nude mice in order to evaluate the tumorigenic potency of the α2δ2 subunit. We show that α2δ2-overexpressing PCA LNCaP cells are more tumorigenic than control LNCaP cells when injected into nude mice. In addition, gabapentin, a ligand of α2δ2, reduces tumor development in LNCaP xenografts. Finally, we show that the action of α2δ2 on tumor development occurs not only through a stimulation of proliferation, but also through a stimulation of angiogenesis, via an increased secretion of vascular endothelial growth factor in cells overexpressing α2δ2.


Subject(s)
Calcium Channels/physiology , Cell Proliferation , Cell Transformation, Neoplastic , Neovascularization, Pathologic/etiology , Prostatic Neoplasms/etiology , Animals , Calcium/metabolism , Calcium Channels/genetics , Cell Line, Tumor , Homeostasis , Humans , Male , Mice , Prostatic Neoplasms/blood supply , Prostatic Neoplasms/pathology , Vascular Endothelial Growth Factor A/metabolism
2.
Oncogene ; 28(15): 1792-806, 2009 Apr 16.
Article in English | MEDLINE | ID: mdl-19270724

ABSTRACT

Accumulating data point to K(+) channels as relevant players in controlling cell cycle progression and proliferation of human cancer cells, including prostate cancer (PCa) cells. However, the mechanism(s) by which K(+) channels control PCa cell proliferation remain illusive. In this study, using the techniques of molecular biology, biochemistry, electrophysiology and calcium imaging, we studied the expression and functionality of intermediate-conductance calcium-activated potassium channels (IK(Ca1)) in human PCa as well as their involvement in cell proliferation. We showed that IK(Ca1) mRNA and protein were preferentially expressed in human PCa tissues, and inhibition of the IK(Ca1) potassium channel suppressed PCa cell proliferation. The activation of IK(Ca1) hyperpolarizes membrane potential and, by promoting the driving force for calcium, induces calcium entry through TRPV6, a cation channel of the TRP (Transient Receptor Potential) family. Thus, the overexpression of the IK(Ca1) channel is likely to promote carcinogenesis in human prostate tissue.


Subject(s)
Calcium/metabolism , Intermediate-Conductance Calcium-Activated Potassium Channels/physiology , Prostatic Neoplasms/pathology , Benzimidazoles/pharmacology , Calcium Channels/physiology , Cell Line, Tumor , Cell Proliferation , Cyclin-Dependent Kinase Inhibitor p21/analysis , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p27 , G1 Phase , Humans , Intermediate-Conductance Calcium-Activated Potassium Channels/analysis , Intracellular Signaling Peptides and Proteins/analysis , Male , Membrane Potentials , Prostatic Neoplasms/metabolism , RNA, Messenger/analysis , S100 Proteins/analysis , TRPV Cation Channels/physiology , Tumor Suppressor Protein p53/physiology
3.
Endocr Relat Cancer ; 13(1): 181-95, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16601287

ABSTRACT

Neuroendocrine differentiation (NED) has been implicated in prostate cancer progression and hormone-therapy failure. Neuroendocrine cells are non-proliferating and escape apoptotic cell death, although their origin and the causes of their apoptotic resistance have as yet been poorly elucidated. This study demonstrates a new mechanism involved in controlling NED. We report that epidermal growth factor (5-50 ng/ml) promotes neuroendocrine-like differentiation of androgen-independent DU145 prostate cancer cells. This differentiation is associated with an increase in the expression of Neuron Specific Enolase (NSE) and a reduction in cell proliferation and is blocked by inhibiting tyrosine kinase activity with genistein and with compound 56 (C56). An increase in the cAMP level, using dibutryl cAMP (db-cAMP) (1 mM) and isobutylmethylxanthine (100 microM), does not promote NED by itself, but does increase the effect of EGF on NED. In addition, EGF-induced NED protects cells from apoptosis induced with thapsigargin (1 microM) by reducing the thapsigargin-induced cytosolic calcium overload. In order to describe how EGF-induced NED protects cells against thapigargin-induced calcium overload we investigated the spatiotemporal calcium signalling linked to apoptosis. By using thapsigargin in various conditions on DU145 cells and using micro-fluorimetric calcium measurements, we show that depletion of intracellular calcium store induces apoptosis and that the amplitude and duration of the capacitive calcium entry are two apoptosis-modulating parameters. We show that protection against thapsigargin-induced apoptosis conferred by NED is achieved by reducing the amount and the speed of calcium that can be released from calcium pools, as well as modulating the amplitude of the subsequent calcium entry.


Subject(s)
Androgens/metabolism , Apoptosis/drug effects , Cell Differentiation/drug effects , Epidermal Growth Factor/pharmacology , Neoplasms, Hormone-Dependent/pathology , Neurosecretory Systems/drug effects , Prostatic Neoplasms/pathology , Antineoplastic Agents/pharmacology , Calcium/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Enzyme Inhibitors/pharmacology , Genistein/pharmacology , Humans , Male , Neoplasms, Hormone-Dependent/drug therapy , Neoplasms, Hormone-Dependent/metabolism , Phosphopyruvate Hydratase/metabolism , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Thapsigargin/pharmacology
4.
Endocr Relat Cancer ; 12(2): 367-82, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15947109

ABSTRACT

TRPM8 (melastatine-related transient receptor potential member 8), a member of the transient receptor potential (TRP) superfamily of cation channels, has been shown to be a calcium-channel protein. TRPM8 mRNA has also been shown to be overexpressed in prostate cancer and is considered to play an important role in prostate physiology. This study was designed to determine the androgen-regulation mechanisms for TRPM8 mRNA expression and to identify the phenotype of TRPM8-expressing cells in the human prostate. Our findings show that trpm8 gene expression requires a functional androgen receptor. Furthermore, this article argues strongly in favour of the fact that the trpm8 gene is a primary androgen-responsive gene. Single-cell reverse transcriptase PCR and immunohistochemical experiments also showed that the trpm8 gene was mainly expressed in the apical secretory epithelial cells of the human prostate and trpm8 down-regulation occurred during the loss of the apical differentiated phenotype of the primary cultured human prostate epithelial cells. The androgen-regulated trpm8 expression mechanisms are important in understanding the progression of prostate cancer to androgen-independence. These findings may contribute to design a strategy to predict prostate cancer status from the TRPM8 mRNA level. Furthermore, as the TRPM8 channel is localized in human prostate cells, it will be interesting to understand its physiological function in the normal prostate and its potential role in prostate cancer development.


Subject(s)
Gene Expression Regulation, Neoplastic , Ion Channels/genetics , Neoplasm Proteins/genetics , Prostatic Neoplasms/genetics , Receptors, Androgen/physiology , 5-alpha-Dihydroprogesterone/metabolism , 5-alpha-Dihydroprogesterone/pharmacology , Androgens/metabolism , Epithelial Cells/chemistry , Epithelial Cells/metabolism , Humans , Ion Channels/metabolism , Male , Myocytes, Smooth Muscle/chemistry , Myocytes, Smooth Muscle/metabolism , Neoplasm Proteins/metabolism , Promoter Regions, Genetic/genetics , Prostate/cytology , Prostate/metabolism , Prostatic Neoplasms/metabolism , RNA, Messenger/analysis , RNA, Messenger/metabolism , Receptors, Androgen/genetics , Response Elements , TRPM Cation Channels , Tumor Cells, Cultured
5.
Cell Calcium ; 34(1): 75-85, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12767895

ABSTRACT

This study investigates the calcium mechanisms involved in growth arrest induced by extracellular ATP in DU-145 androgen-independent human prostate cancer cells. Exposure of DU-145 cells to 100 microM ATP produced an increase in cytoplasmic calcium concentration ([Ca(2+)](i)), due to a mobilization of calcium from the endoplasmic reticulum stores and to subsequent capacitative calcium entry (CCE). We have shown that this [Ca(2+)](i) increase occurs after stimulation by ATP of the phospholipase C (PLC) pathway. For the first time, we have identified the inositol 1,4,5-trisphosphate receptor (IP(3)R) isoforms expressed in this cell line and have demonstrated a participation of protein kinase C in CCE. Using fluorescence imaging, we have shown that a long-term treatment with ATP leads to a decrease in the intraluminal endoplasmic reticulum calcium concentration as well as in the amount of releasable Ca(2+). Modulating extracellular free calcium concentrations indicated that variations in [Ca(2+)](i) did not affect the ATP-induced growth arrest of DU-145 cells. However, treating cells with 1 nM thapsigargin (TG) to deplete intracellular calcium pools prevented the growth arrest induced by ATP. Altogether, these results indicate that growth arrest induced in DU-145 cells by extracellular ATP is not correlated with an increase in [Ca(2+)](i) but rather with a decrease in intracellular calcium pool content.


Subject(s)
Adenosine Triphosphate/metabolism , Calcium Signaling/physiology , Calcium/metabolism , Carcinoma/metabolism , Prostatic Neoplasms/metabolism , Adenosine Triphosphate/pharmacology , Calcium/pharmacology , Calcium Channels/drug effects , Calcium Channels/genetics , Calcium Channels/metabolism , Calcium Signaling/drug effects , Carcinoma/physiopathology , Cell Division/drug effects , Cell Division/physiology , Cell Line, Tumor , Cytoplasm/drug effects , Cytoplasm/metabolism , Down-Regulation/drug effects , Down-Regulation/physiology , Endoplasmic Reticulum/drug effects , Endoplasmic Reticulum/metabolism , Humans , Inositol 1,4,5-Trisphosphate Receptors , Intracellular Fluid/drug effects , Intracellular Fluid/metabolism , Male , Prostatic Neoplasms/physiopathology , Protein Kinase C/metabolism , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Thapsigargin/pharmacology , Type C Phospholipases/drug effects , Type C Phospholipases/metabolism
6.
Biol Cell ; 94(7-8): 545-52, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12566227

ABSTRACT

A calcium dependent-chloride current (I(ni)) was recorded in Xenopus oocytes injected with total RNA from chicory leaf tissues, following depolarization from -35 to +60 mV. However, the signal transduction mechanism mediating I(ni) is unknown. The development of this current was mimicked by intracellular injection of the second messenger InsP(3) in control (non-injected) oocytes. Moreover, InsP(3) injection after I(ni) rundown did not reinitiate the current. The same phenomenon was observed following a second injection into control oocytes. Measurement of InsP(3) production in injected oocytes showed a net increase in the InsP(3) level on depolarization. Moreover, extracellular application of caffeine (5 mM) significantly reduced the number of oocytes displaying I(ni). Also, extracellular application of U-73122, a potent PLC inhibitor, clearly reduced the occurrence of I(ni). These data provide the first evidence that the calcium homeostasis mechanism induced by heterologous expression of total RNA from chicory leaves involves the InsP(3) signaling pathway.


Subject(s)
Calcium/metabolism , Cichorium intybus , Inositol 1,4,5-Trisphosphate/physiology , Plant Leaves/genetics , RNA, Plant/physiology , Second Messenger Systems/physiology , Animals , Chloride Channels , Electrophysiology , Microinjections , Oocytes , RNA, Plant/biosynthesis , RNA, Plant/isolation & purification , Type C Phospholipases/metabolism , Xenopus laevis
7.
Recept Channels ; 7(5): 345-56, 2001.
Article in English | MEDLINE | ID: mdl-11697078

ABSTRACT

MCF-7 cells express voltage-activated K+ channels. In the present study, we used the patch-clamp and RT-PCR techniques to investigate the involvement of these channels during the cell cycle progression. The outward rectifier current (IK) recorded during depolarization was almost completely suppressed by the classical K+ channel blocker tetraethylammonium (TEA) in MCF-7 cells. TEA also inhibited cell proliferation, as measured with 3H-thymidine incorporation. Moreover, profound changes were observed in both the resting membrane potential (RMP) and IK during the release from the G0/G1 phase of the cell cycle. MCF-7 cells arrested in G0/G1 were depolarized (-26.3 +/- 10 mV, n = 30) and IK-density was small (9.4 +/- 5.6 pA/pF, n = 60) compared to cells progressing in the G1 phase (RMP = -60 +/- 7.9 mV; n = 35 and IK-density = 30.2 +/- 8.5 pA/pF; n = 76). IK was highly sensitive to Mg2+, astemizole and TEA (10 mM). Extracellular perfusion of 5 mM Mg2+ dramatically slowed the activation and perfusion of 2 microM astemizole inhibited both IK (20 +/- 3%) and cell proliferation (23%). Moreover, the h-EAG mRNA expression was modulated during the cell cycle. Thus, these data suggested that h-EAG K+ channels play a role in controlling the proliferation and/or cell cycle.


Subject(s)
Breast Neoplasms/metabolism , Potassium Channels/metabolism , Potassium/metabolism , Astemizole/pharmacology , Biological Transport , Cell Cycle/drug effects , Electric Conductivity , Ether-A-Go-Go Potassium Channels , Female , G1 Phase/drug effects , Growth Inhibitors/pharmacology , Humans , Membrane Potentials , Potassium Channel Blockers/pharmacology , Resting Phase, Cell Cycle/drug effects , Tetraethylammonium/pharmacology , Tumor Cells, Cultured
8.
Parasitol Res ; 87(3): 239-44, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11293573

ABSTRACT

Previous studies have shown that ferrochloroquine (FQ) exhibited an antimalarial activity against Plasmodium spp. The present work confirmed this activity, described the curative effect on P. vinckei and investigated the FQ toxicity in vitro and in vivo. The in vitro and in vivo growth inhibition of P. falciparum and P. berghei N, respectively, showed that FQ antimalarial activity was 1.5-10 times more potent than chloroquine. FQ completely inhibited the in vivo development of both chloroquine-susceptible and resistant P. vinckei strains and protected mice from lethal infection at a dose of 8.4 mg kg(-1) day(-1) given for 4 days subcutaneously or orally. This curative effect was 5-20 times more potent than chloroquine, according to the strains' resistance to chloroquine. At this curative dose, no clinical changes were observed in mice up to 14 days after the last administration. Nevertheless, the acute toxicity and lethality of ferrochloroquine seemed to be dependent on gastric surfeit. The FQ security index determined in vitro confirmed that it might be a promising compound.


Subject(s)
Antimalarials/pharmacology , Chloroquine/pharmacology , Malaria, Falciparum/veterinary , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Rodent Diseases/prevention & control , Administration, Oral , Animals , Cells, Cultured , Chloroquine/analogs & derivatives , Drug Resistance , Female , Ferrous Compounds , Injections, Subcutaneous , Lymphoma , Malaria, Falciparum/prevention & control , Mice , Plasmodium berghei/growth & development , Plasmodium falciparum/growth & development
9.
Biochem Biophys Res Commun ; 278(2): 272-7, 2000 Nov 19.
Article in English | MEDLINE | ID: mdl-11097830

ABSTRACT

Electrophysiological, immunocytochemical, and RT-PCR methods were used to identify a K(+) conductance not yet described in MCF-7 human breast cancer cells. A voltage-dependent and TEA-sensitive K(+) current was the most commonly observed in these cells. The noninactivating K(+) current (I(K)) was insensitive to iberiotoxin (100 nM) and charybdotoxin (100 nM) but reduced by alpha-dendrotoxin (alpha-DTX). Perfusion of alpha-DTX reduced a fraction of I(K) amplitude in a dose-dependent manner (IC(50) = 0.6 +/- 0.3 nM). This DTX sensitive I(K) exhibited a voltage threshold at -20 mV and was not inactivated. The time constant of activation was 5.3 +/- 2.2 ms measured at +60 mV. The averaged half-activation potential and slope factor values were 14 +/- 1.6 mV and 10 +/- 1.4, respectively. Immunocytochemical analysis demonstrated that plasma membrane was labeled by anti-Kv1.1 but not by anti-Kv1.2 nor anti-Kv1.3 antibodies. Furthermore, only Kv1.1 mRNA was detected in MCF-7 cells. Incubation in 1 and 10 nM alpha-DTX reduced cell proliferation by 20 and 30%, respectively. These data provide the first evidence of Kv1.1 K(+) channels expression in MCF-7 cells and indicate that these channels are implicated in cell proliferation.


Subject(s)
Breast Neoplasms/metabolism , Cell Division , Potassium Channels, Voltage-Gated , Potassium Channels/metabolism , Breast Neoplasms/pathology , Elapid Venoms/pharmacology , Humans , Immunohistochemistry , Kv1.1 Potassium Channel , Potassium Channels/drug effects , Potassium Channels/physiology , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
10.
J Med Chem ; 43(7): 1311-9, 2000 Apr 06.
Article in English | MEDLINE | ID: mdl-10753468

ABSTRACT

A series of compounds including 4-amino (1), 3-amino (2), 4-nitro (3), 2-methyl-3-amino (4), 2-methyl-3-nitro (5), 2-methyl-4-amino (6), 2-methyl-4-nitro (7), 2-methyl-5-amino (8), 2-methyl-5-nitro (9), 2-methyl-6-amino (10), 2-methyl-6-nitro (11), 2,6-dimethyl (12), 2-methyl-3-carboxy (13), 2-methoxycarbonyl (14), 2-methyl-4-methoxy (15), 2,4-dimethoxy (16), 2-chloro-4-amino (17), and 2-chloro-4-nitro (18) N-phenyl substituents of phthalimide were evaluated along with N-[3-methyl-(2-pyridinyl)]phthalimide (19), N-(3-amino-2-methylphenyl)succinimide (20), and phenytoin for anticonvulsant and neurotoxic properties. Initial screening in the intraperitoneal (ip) maximal electroshock-induced seizure (MES) test and the subcutaneous pentylenetetrazol-induced seizure (scPtz) test in mice led to the selection of 1, 2, 4, 10, 12, 17, and 19 for oral MES evaluation in rats. The resultant ED(50) values for 4, 10, 17, and phenytoin were 8.0, 28.3, 5.7 and 29.8 mg/kg, respectively. In the batrachotoxin affinity assay, IC(50) values for 17 and phenytoin were 0.15 and 0.93 microM, respectively, and in the recently validated magnesium deficiency-dependent audiogenic seizure test, ED(50) values of 5.2 and 23 mg/kg were obtained for 17 and phenytoin, respectively. Electrophysiology studies on compound 17 point out its ability to (i) potentiate GABA-evoked current responses with a failure to directly activate the GABAA receptor and (ii) to affect, at 100 microM excitatory non NMDA, but not NMDA, receptors with a 25% block of kainate-evoked response. Electrophysiology measurements on voltage-gated sodium channels in N1E-115 neuroblastoma cells confirm voltage-dependent block of these channels by compound 17. In view of its interaction with multiple ion channels, one would predict that compound 17 might be active in a wide range of seizure models.


Subject(s)
Anticonvulsants/pharmacology , Phthalimides/pharmacology , Administration, Oral , Animals , Anticonvulsants/chemical synthesis , Anticonvulsants/toxicity , Batrachotoxins/metabolism , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Cerebral Cortex/physiology , Convulsants , Electroshock , Excitatory Amino Acid Agonists/pharmacology , In Vitro Techniques , Ion Channel Gating , Kainic Acid/pharmacology , Magnesium Deficiency/complications , Mice , N-Methylaspartate/pharmacology , Patch-Clamp Techniques , Pentylenetetrazole , Phenytoin/pharmacology , Phthalimides/chemical synthesis , Phthalimides/toxicity , Rats , Seizures/drug therapy , Seizures/etiology , Sodium Channel Blockers , Structure-Activity Relationship , Synaptosomes/metabolism , Tumor Cells, Cultured , gamma-Aminobutyric Acid/pharmacology
11.
Br J Haematol ; 103(1): 52-9, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9792289

ABSTRACT

The role of endogenous and internalized catalase in the protection of Plasmodium against oxidant stress was studied. Catalase activities were measured in isolated Plasmodium falciparum at different stages of intererythrocytic development. Activities measured at late schizont stages were compared to parasite markers (glutamate dehydrogenase, SOD) and to red blood cell markers (haemoglobin, Cu/Zn-SOD). The fate of the host cell catalase in the parasite digestive system was studied by immunoelectron microscopy using monoclonal antibodies. The internalized catalase appeared to be dissociated in the digestive system of the parasite and inactivated. To examine the protective role of the endogenous and internalized catalase in the parasite protection against oxidant stress, parasites were cultivated at two oxygen concentrations (5% and 20%) in inhibited catalase red blood cells. These experiments suggested that the catalases present both in red blood cell and parasite are not essential when parasites are cultivated under 5% oxygen, but are necessary to protect the parasite under 20% oxygen. Catalase may not be the main protective enzyme involved in the protection of P. falciparum in standard in vitro culture conditions, but may become critical under the higher oxygen tensions conditions encountered in vivo.


Subject(s)
Catalase/metabolism , Erythrocytes/enzymology , Oxygen/physiology , Plasmodium falciparum/enzymology , Animals , Erythrocytes/parasitology , Humans , Immunohistochemistry
12.
Mol Med ; 3(8): 544-52, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9307982

ABSTRACT

BACKGROUND: Human natural antibodies have been found that owe their candidacidal action to the mimicry of a yeast killer toxin produced by the yeast Pichia anomala (PaKT). Candidacidal human natural antibodies (KTAb) are elicited by and bind to a KT receptor (PaKTR) present on the cell surface of infectious PaKT-sensitive microorganisms. Because of the recognized susceptibility of Pneumocystis carinii organisms to PaKT upon the occurrence of specific PaKTR, we examined whether human natural KTAb could also bind to and inhibit P. carinii. MATERIALS AND METHODS: Immunoaffinity-purified KTAb from the vaginal fluid of patients affected by candidiasis were tested and compared with PaKT for their ability to inhibit rat-derived P. carinii attachment to epithelial lung cells as well as infectivity to nude rats. Immunofluorescence studies were also performed by biotinylated PaKT in competition with human KTAb to establish their specific binding to PaKTR on the surface of rat-derived and human P. carinii organisms. RESULTS: Human natural candidacidal KTAb exerted a strong, specific inhibitory activity against rat-derived P. carinii organisms that are susceptible to PaKT itself. The antimicrobial activity of human KTAb was abolished by adsorption with a specific PaKT-neutralizing mAb KT4. Immunofluorescence studies of competition with PaKT showed that human KTAb efficiently bind to the specific PaKTR on the surface of rat-derived and human P. carinii organisms. CONCLUSIONS: The results strongly suggest that human KTAb, elicited by a common transphyletic receptor of different pathogenic microorganisms during infection, may play a role in antibody-mediated cross-immunity and, if properly engineered, as functionally equivalent recombinant antibodies they could exert a therapeutic activity against pneumocystosis in vivo.


Subject(s)
Antibodies, Fungal/immunology , Candida/immunology , Mycotoxins/immunology , Pneumocystis/immunology , Animals , Antibodies, Fungal/isolation & purification , Antibodies, Monoclonal , Antibody Specificity , Candidiasis, Vulvovaginal/immunology , Cell Adhesion/immunology , Female , Fibroblasts/microbiology , Humans , Immunity, Innate , Killer Factors, Yeast , Lung/microbiology , Male , Neutralization Tests , Pneumonia, Pneumocystis/microbiology , Rats , Rats, Nude , Receptors, Cell Surface/metabolism , Vagina/immunology
14.
Magnes Res ; 8(2): 159-67, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7547177

ABSTRACT

Severe magnesium deficiency protects mice against infections by Plasmodium Spp. and Babesia hylomysci which invade mature erythrocytes. By contrast severe magnesium deficiency does not protect against parasite infections by P. berghei which invades reticulocytes, Toxoplasma gondii which invades macrophages, and Trypanosoma brucei which lives free in blood. The results indicate that the infectious response depends on the severity of magnesium deficiency and on the parasite species. The decrease in red blood cell magnesium and increased oxidant stress are possible explanations for the protective effect of magnesium deficiency.


Subject(s)
Magnesium Deficiency/parasitology , Protozoan Infections/metabolism , Animals , Babesia/growth & development , Babesia/ultrastructure , Babesiosis/metabolism , Erythrocytes/metabolism , Erythrocytes/parasitology , Host-Parasite Interactions , Immunity, Innate , Magnesium/metabolism , Magnesium Deficiency/blood , Malaria/metabolism , Mice , Plasmodium/genetics , Plasmodium/growth & development , Plasmodium/ultrastructure , Protozoan Infections/parasitology , Reticulocytes/parasitology , Time Factors , Toxoplasma/growth & development , Toxoplasmosis, Animal/metabolism , Trypanosoma brucei brucei/growth & development , Trypanosoma brucei brucei/ultrastructure , Trypanosomiasis/metabolism
17.
Parasitology ; 108 ( Pt 3): 245-8, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8022652

ABSTRACT

Mice were fed diets containing 960 mg (control), 100 mg (moderately Mg deficient) and 30 mg (severely Mg deficient) of Mg/kg. After 20 days, mice were inoculated with Babesia hylomysci (from Dr. Wery, Anvers, Belgium). Significant increases in RBC Mg levels were observed following infection. All the control and moderately deficient mice died from infection, whereas the severely Mg-deficient diet protected mice against infection, as shown by a decrease in parasitaemia and mortality. The decrease in RBC Mg, modifications in membrane properties and increased oxidant stress are possible explanations for the protective effect of severe Mg deficiency. When mice were maintained for 2 months after inoculation on a severely Mg-deficient diet and were then switched to a control diet, all survived and had low parasitaemias. After 1 month, these mice were rechallenged with B. hylomysci and 89% survived.


Subject(s)
Babesiosis/immunology , Magnesium Deficiency/immunology , Magnesium/administration & dosage , Animals , Babesiosis/blood , Babesiosis/complications , Erythrocytes/chemistry , Erythrocytes/parasitology , Female , Magnesium/blood , Magnesium Deficiency/complications , Mice
18.
Pacing Clin Electrophysiol ; 3(2): 162-70, 1980 Mar.
Article in English | MEDLINE | ID: mdl-6160505

ABSTRACT

The authors describe a case of so-called "intra-atrial reentry," associated with sinus node dysfunction. The spontaneous initiation of the tachycardia was always preceded by a sinus pause, and external atrial pacing prevented the appearance of tachycardia. Thus an atrial pacemaker was implanted, and after several months, the atrial dysrhythmias disappeared completely, despite interruption of the antiarrhythmic drugs. When a pacemaker dysfunction occurred, the sinus node dysfunction and the tachycardia reappeared. This is analogous with the "incessant" tachycardias seen in the WPW syndrome, and must be differentiated from the usual forms of the sick sinus syndrome which require both a pacemaker and antiarrhythmic drugs.


Subject(s)
Pacemaker, Artificial , Tachycardia/prevention & control , Adult , Diagnosis, Differential , Electrodes, Implanted , Electrophysiology , Female , Heart Atria/physiopathology , Heart Conduction System/physiology , Humans , Recurrence , Sick Sinus Syndrome/physiopathology , Sinoatrial Node/physiopathology , Tachycardia/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...